Superficial Vein Thrombosis
Thieme. All rights reserved..
EPIDEMIOLOGY AND RISK FACTORS: A large German registry on superficial vein thrombosis (SVT) documents that risk profiles, clinical presentation and treatment patterns are highly variable in patients with SVT, including a large variation in anticoagulation treatment modalities, intensities and durations. Inspite of a high percentage of initial anticoagulation there is a substantial risk of subsequent venous thromboembolism (VTE), recurrences or extension after three months. Inspite of current guideline recommendations, one third of the patients receives heparins, oral anticoagulants or no anticoagulation at all. At initial presentation about one quarter of the patients with SVT have a concomitant, frequently asymptomatic VTE. Risk factors for this complication include prior hospitalization, immobilization, prior VTE, autoimmune disorders, higher age, cancer and SVT occurring in a non-varicose veins or SVT-extension into the perforator veins. These risk factors are also associated with thromboembolic complications during follow-up.
TREATMENT: Based on a large placebo-controlled trial with clinical endpoints (The CALISTO-Study), guidelines recommend Fondaparinux 2.5 mg once daily administered over 4 to 6 weeks. Alternatively, an intermediate dose of low molecular weight heparin can be considered. In high-risk patients, rivaroxaban 10 mg once daily was noninferior compared to Fondaparinux. A rebound of VTE recurrences was observed in both study arms after treatment had been discontinued after 45 days. Further studies are required to determine whether treatment needs to be extended beyond 45 days in high-risk patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Deutsche medizinische Wochenschrift (1946) - 146(2021), 19 vom: 22. Okt., Seite 1237-1242 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Oberflächliche Venenthrombose |
|---|
| Beteiligte Personen: |
Bauersachs, Rupert M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 20.01.2022 Date Revised 20.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1286-2153 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330951017 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330951017 | ||
| 003 | DE-627 | ||
| 005 | 20231225212411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-1286-2153 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM330951017 | ||
| 035 | |a (NLM)34553346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Bauersachs, Rupert M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Superficial Vein Thrombosis |
| 246 | 3 | 3 | |a Oberflächliche Venenthrombose |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2022 | ||
| 500 | |a Date Revised 20.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a EPIDEMIOLOGY AND RISK FACTORS: A large German registry on superficial vein thrombosis (SVT) documents that risk profiles, clinical presentation and treatment patterns are highly variable in patients with SVT, including a large variation in anticoagulation treatment modalities, intensities and durations. Inspite of a high percentage of initial anticoagulation there is a substantial risk of subsequent venous thromboembolism (VTE), recurrences or extension after three months. Inspite of current guideline recommendations, one third of the patients receives heparins, oral anticoagulants or no anticoagulation at all. At initial presentation about one quarter of the patients with SVT have a concomitant, frequently asymptomatic VTE. Risk factors for this complication include prior hospitalization, immobilization, prior VTE, autoimmune disorders, higher age, cancer and SVT occurring in a non-varicose veins or SVT-extension into the perforator veins. These risk factors are also associated with thromboembolic complications during follow-up | ||
| 520 | |a TREATMENT: Based on a large placebo-controlled trial with clinical endpoints (The CALISTO-Study), guidelines recommend Fondaparinux 2.5 mg once daily administered over 4 to 6 weeks. Alternatively, an intermediate dose of low molecular weight heparin can be considered. In high-risk patients, rivaroxaban 10 mg once daily was noninferior compared to Fondaparinux. A rebound of VTE recurrences was observed in both study arms after treatment had been discontinued after 45 days. Further studies are required to determine whether treatment needs to be extended beyond 45 days in high-risk patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Fondaparinux |2 NLM | |
| 650 | 7 | |a J177FOW5JL |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Deutsche medizinische Wochenschrift (1946) |d 1946 |g 146(2021), 19 vom: 22. Okt., Seite 1237-1242 |w (DE-627)NLM000002852 |x 1439-4413 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2021 |g number:19 |g day:22 |g month:10 |g pages:1237-1242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1286-2153 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2021 |e 19 |b 22 |c 10 |h 1237-1242 | ||